Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “efficacy determination”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed1976

Test method for determination of virucidal efficacy of liquid surface disinfectants.

A test method was developed incorporating AOAC use-dilution stainless steel Penicylinders and H.Ep.-2 tissue culture cells for the evaluation of disinfectants as virucides. The subsequent collaborative study using Herpes simplex and poliovirus type 1 in evaluation against a quaternary ammonium compound, phenolic, and iodiphor disinfectants indicated that the basic test procedure is sound. However, an improved virus concentration technique and a modified method for drying virus-contaminated cylinders are recommended. In addition, other types of disinfectants and test viruses should be included in order to demonstrate that the procedure is versatile as well as reproducible.

Antiviral Agents↗
PubMed1977

Issues along the Potomac: "efficacy" and "technology transfer".

"Efficacy" and "technology transfer" are currently subjects of intense interest to health-related agencies in Washington. These jargon terms refer to assuring that useful knowledge is applied to all who need it and that the application of ineffective technology is discouraged. There is no public or private institution responsible for either assembling data on efficacy or for quaranteeing that necessary studies are undertaken. The determination of efficacy is important for cost control, quality assurance, planning, and any national health insurance plan. Whether engaged principally in practice, teaching, or research, it is important for physicians not only to be conversant with these issues but to participate in the resolution of the questions involved.

Cost-Benefit Analysis↗
PubMed1976

Assay of topical corticosteroids. Efficacy of suppression of experimental Rhus dermatitis in humans.

Rhus dermatitis, experimentally induced in humans, was used as a model for determining the efficacy of various proprietary topical steroids. One-centimeter squares of vesicular dermatitis were induced by patch application of Rhus oleoresin. The steroids were then applied without occlusion once daily for four days, with readings of the therapeutic effect taken on the fifth day. Only potent steroids provided unequivocal suppression in this severe test. The rank order of efficacy corresponded to clinical experience. Cream and ointment formulations of the same steroid at the same strength did not differ. High strength preparations were more effective than regular strengths. Relief of pruritus was an important early effect of efficaceous steroids.

Administration, Topical↗
PubMed1977

Nippostronglylus brasiliensis infection in the rat: effect of iron and protein deficiency and dexamethasone on the efficacy of benzimidazole anthelmintics.

Malnutrition, anaemia, and gut parasites are commonly interrelated. Using the Nippostrongylus brasiliensis-rat model, the effect of iron and protein deficiency on the efficacy of benzimidazole anthelmintics was studied. It was demonstrated that the anthelmintics mebendazole and fenbendazole were significantly less effective in eradicating parasites when animals were deficient in iron and protein. This decreased efficacy of anthelmintics in iron and protein deficiency could not be overcome by intraperitoneal administration of the drug. Since nutritional deficiencies may act via impairment of the immune response, anthelmintic efficacy was determined in adequately nourished rats treated with the immunosuppressive drug dexamethasone. A similar decrease in efficacy of mebendazole was shown when these animals were treated with dexamethasone. Thus it is possible that lowered anthelmintic efficacy in iron and protein deficient animals is mediated by immune deficiency. These findings may be relevant to anthelmintic programmes in malnourished communities.

Animals↗
PubMed2026

The potential clinical benefit of routine comprehensive genomic profiling in non-small cell lung cancer for the detection of prognostic co-mutations - A multicenter next generation sequencing study.

INTRODUCTION: Non-driver mutations such as TP53, STK11 and KEAP1 are clinically relevant in determining immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC). The aim of this study is to determine the prevalence and clinical relevance of variations in TP53, STK11 and KEAP1 in patients in the analysis of NSCLC, using targeted next-generation sequencing. METHODS: This real-life prospective multicenter cohort study from July 2022 until October 2023 utilized samples of patients in the analysis of NSCLC. The samples were subjected to a targeted DNA NGS panel and, if indicated, RNA sequencing. The outcome of the molecular diagnostics was retrieved, including driver alterations and more in-depth analysis of TP53, STK11 and KEAP1. RESULTS: In 134 of the 437 samples an actionable genomic alteration (AGA) was detected. Of the remaining samples, 213 carried a mutation in either TP53, STK11 and/or KEAP1, while 90 harbored either variants of unknown significance (VUS) (16) or no variant (74). In-depth analysis showed 77 alterations of STK11, with 56 pathogenic and 21 VUS. Most STK11 variants were identified in exon 1, which is hypothesized to be correlated to an oncogenic isoform. Moreover, variants in KEAP1 were mostly VUS, with 48 VUS and 24 mutations. Lastly, 264 TP53 alterations, of which 249 pathogenic and 15 VUS, occurred, with an even spread in the DNA-binding domain. CONCLUSION: This study demonstrated the broad spectrum of variants in STK11, KEAP1 and TP53 in routine panel-based DNA NGS, with 70.3% of the samples without AGA showing a potential clinically relevant mutation in TP53, STK11 and/or KEAP1.

Humans↗
PubMed1978

Acute appendicitis: efficacy of prophylactic preoperative antibiotics in the reduction of septic morbidity.

The course of 200 patients who recently underwent appendectomy at UCLA for acute appendicitis has been reviewed to determine the efficacy of preoperative systemic antibiotic prophylaxis in reducing septic morbidity after surgery. Among those with nonperforated appendicitis who were given gentamycin and clindamycin preoperatively, a reduction of infection rate from 10.2 to 5.3 per cent was found when compared with patients who received no antibiotics.

Adolescent↗
PubMed1979

The use of plasma androstenedione in monitoring therapy of patients with congenital adrenal hyperplasia.

Therapy of congenital adrenal hyperplasia tranditionally is monitored by the amount of urinary 17-KS. However, 24-hour urine collections are difficult to obtain and are often unreliable. Measurement of the plasma concentrations of androgens, such as delta or T, would therefore be a more convenient way to determine the efficacy of treatment. Over a period of 2 to 24 months, 23 patients were periodically assessed by clinical examination, bone age, and determinations of plasma delta, plasma T, and 24-hour urinary 17-KS. Plasma T concentration correlated well with clinical control in females and in preadolescent males, but not in infant and pubertal males. By contrast, plasma delta concentration correlated well with clinical control in either sex, regardless of stage of puberty. The present study suggests that monitoring plasma delta concentration is useful in the long-term management of patients with CAH.

17-Ketosteroids↗
PubMed2026

Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis.

BACKGROUND: Peripheral artery disease (PAD) is a common atherosclerotic disorder characterized by progressive arterial narrowing in the limbs. This study aims to determine the efficacy and safety of rivaroxaban, focusing on major cardiovascular events, limb outcomes, and bleeding risks. METHODS: PubMed, Cochrane, and EMBASE were searched for randomized controlled trials (RCTs) and nonrandomized comparative studies that compared rivaroxaban, either alone or in combination with aspirin, to placebo or standard care such as antiplatelet therapy. Risk ratios and hazard ratios with 95% confidence intervals were pooled using R v4.5.1 with an appropriate random-effects model applied. Subgroup analyses were performed according to rivaroxaban plus aspirin versus rivaroxaban alone. RESULTS: A total of 39,991 participants across 6 studies were included. Compared with control, use of rivaroxaban was linked to a significant reduction in composite efficacy outcomes (relative risk [RR] = 0.84, 95% confidence interval [CI] 0.78-0.91, P < 0.001), risk of acute limb ischemia (RR = 0.65, 95% CI 0.55-0.78, P < 0.001), and thromboembolism (RR = 0.60, 95% CI 0.38-0.97, P = 0.037). Although rivaroxaban plus aspirin failed to show a significant reduction in the risk of amputation, rivaroxaban alone reported a significant risk reduction (RR = 0.50, 95% CI 0.30-0.85, P = 0.003). However, its use was associated with a significantly higher risk of major bleeding (hazard ratio [HR] = 1.54, 95% CI 1.38-1.72, P < 0.001) and International Society on Thrombosis and Hemostasis-defined bleeding (RR = 1.45, 95% CI 1.19-1.76, P < 0.001). No significant differences were observed for stroke, myocardial infarction, major adverse limb events, fatal bleeding, mortality, or cardiovascular mortality. CONCLUSION: Rivaroxaban-based therapy reduced the trial-defined composite efficacy outcome, acute limb ischemia, and thromboembolism in patients with PAD, but increased the risk of major bleeding. These findings support individualized use of rivaroxaban-based therapy in carefully selected patients, balancing ischemic and limb-protective benefits against bleeding risk.

Humans↗
PubMed1977

Intravenous fructose treatment of acute alcohol intoxication. Effects on alcohol metabolism.

This study was designed to determine the efficacy of the intravenous administration of fructose in the treatment of acute alcohol intoxication. The study was prospective and double-blind, with glucose serving as the control. Treatment with glucose and fructose was determined by random selection. Fructose administration did not alter the clinical status or rate of alcohol metabolism as reflected by the decline in serum concentration. In addition, a significant elevation (P less than .05) in serum uric acid and lactate levels occurred in the patients receiving fructose. The results indicate that fructose is of no value in the treatment of acute alcohol intoxication, and produces metabolic abnormalities that could be harmful to the patient.

Adolescent↗
PubMed1979

[Hexacyanoferrate-compounds as indicator substances for the efficacy of antimicrobial agents to desulfuricants (author's transl)].

Hexacyanoferrate-compounds are suitable to indicate the efficacy of antimicrobial substances to sulfate-reducing bacteria. They act as a cytochemical indicator system. (Stübner, 9), e. g. K3FeIII(CN)6 showes FeS formation before any visible blackening of the medium. By using hexacyanoferrate compounds it is easier to determine the efficacy of antimicrobial agents. In addition a microscopical control is recommended to detect damaged or avital bacteria in the limiting concentrations of the agents.

Acridines↗
PubMedDate not supplied

Guidelines for antiinflammatory drug research.

Guidelines have been developed by the Bureau of Drugs, FDA, for antinflammatory drug development. They address the problem of efficacy and safety testing but leave the definition of qualified investigators and appropriate subjects unstated. The natural history of rheumatoid arthritis, the most-studied chronic inflammatory disorder, is not sufficiently appreciated, and "controlled" studies are too narrowly structured to give adequate information. By contrast, other countries speed the review process by emphasizing early toxicity studies and letting the market place determine relative efficacy while long-range safety data are carefully monitored.

Anti-Inflammatory Agents↗
PubMed1979

[Pathophysiology of kidney lesions after temporary ischemia and measures for their prevention].

The efficacy of the so-called "hyperosmolar kidney preservation" is pointed out with respect to protecting the kidney from the otherwise lethal effect of protracted periods of normothermic ischemia. Furthermore the protective effect of various pharmacologic agents against 2 and 3 hours of normothermic ischemia is investigated and the morphology and pathophysiology of renal ischemic damage is pointed out. In further experiments extracorporeal renal operations were performed in 12 dogs to determine the efficacy of a new renal preservation method.

Animals↗
PubMed2026

Host Range and Chemical Control of Cercospora citrullina, the Causal Agent of Watermelon Spot Disease.

This study systematically evaluated cultivation requirements, host range, and chemical control options for Cercospora citrullina causing watermelon spot disease. Among 11 chemically defined media tested, corn meal agar medium supported optimal mycelial growth of C. citrullina, with an average radial growth rate of 56.72 &#xb1; 1.45 mm under controlled conditions (25&#xb0;C, darkness). Host range determination via artificial inoculation of 19 plant species confirmed that the host range of the strain UNL090101 is limited to the Cucurbitaceae species tested, with watermelon (Citrullus lanatus) exhibiting the highest susceptibility, followed by melon (Cucumis melo) and cucumber (Cucumis sativus). Fungicide screening of 17 commercial formulations identified 40% iminoctadine tris (albesilate) WP (EC50 = 2.82 &#x3bc;g&#xb7;liter-1) and 64% mancozeb + 8% cymoxanil (WS) (EC50 = 48.75 &#x3bc;g&#xb7;liter-1) as the most effective treatments, achieving control efficacies of 74.47 and 58.62%, respectively. These findings provide actionable guidelines for optimizing crop rotation, intercropping strategies, and fungicide selection in watermelon production systems.

Cercospora citrullina↗
PubMed1978

Succinylcholine chloride as a euthanatizing agent in dogs.

In order to determine the efficacy of succinylcholine chloride as a euthanatizing agent, the possible situation encountered in mass euthanasia was recreated. While anesthetized or awake, sixteen 2-year-old Beagles of both sexes were subcutaneously injected with either 1.1 g or 11 mg of succinylcholine chloride/kg of body weight. Positive pressure respiration was given to 2 dogs, otherwise the treatment was allowed to run its course. Electrocardiogram, electroencephalogram, and impedance pneumogram recordings were obtained for time comparisons and for determination of the ultimate cause of death.

Animals↗
PubMed1978

Aluminum hydroxide: evaluation of two dosage forms and two dosing schedules in reducing intestinal phosphate absorption.

A crossover, randomized, eight-week trial using eight adult volunteers was undertaken to (1) determine the efficacy of aluminum hydroxide in decreasing gastrointestinal phosphate absorption, (2) compare the effectiveness of "with meal" and "between meal" dosing schedules, and (3) compare the effectiveness of the capsule and liquid dosage forms. Four treatments, each with a daily dose of approximately 6 g, were taken on a three-times-a-day regimen. The effectiveness of the treatment regimens was measured by using two variables: the decrease in total urinary phosphorus excretion, and the increase in the percent tubular reabsorption of phosphorus (TRP). Aluminum hydroxide treatment produced a significant change in urinary phosphorus excretion (p less than 0.0005) and in percent TRP (p less than 0.0005). For the study population, total urinary phosphorus excretion was the determining factor in changing the percent TRP. The increase in TRP and the decrease in total urinary phosphorus excretion was of the same degree regardless of dosage form or dosage schedule. Aluminum hydroxide was effective in decreasing phosphorus absorption as measured in this study. It appears that aluminum hydroxide capsules could be used with equal efficacy as the liquid dosage form in controlling hyperphosphatemia in patients with chronic renal failure who will not comply with a treatment program using the liquid.

Adult↗